Daré Bioscience to Present New Implantable Device in Boston
The DARE-IDDS platform offers programmable, wireless drug delivery and aims to replace daily injections upon future clinical validation.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Would you trust an implantable device to manage your long-term medication doses instead of manual injections?
Daré Bioscience is set to showcase its DARE-IDDS subcutaneous implantable device at the PODD 2026 conference in Boston on October 30, 2026. The device, currently in preclinical development, aims to provide long-acting, reversible drug delivery.
Why it matters
The platform seeks to improve patient adherence by replacing traditional daily injection-based therapies with a programmable, wireless implant. It represents an emerging shift toward long-term, autonomous medical devices.
The device features a storage capacity of over 100 doses, significantly exceeding the single-dose capacity of traditional delivery methods. It remains in the preclinical phase, with no human efficacy benchmarks established.
The players
Daré Bioscience
A San Diego-based biopharmaceutical firm focused on developing clinical-stage therapies and implantable devices for women's health.
Cambridge Consultants
A product development and technology firm that partners with medical device companies to engineer complex, wirelessly connected systems.
The details
The DARE-IDDS device uses a subcutaneous architecture that integrates programmable drug delivery with wireless communication protocols. By embedding the mechanism under the skin, it allows for controlled, long-term release of medication, potentially reducing the frequency of clinic visits. Daré Bioscience developed the platform in collaboration with Cambridge Consultants to manage the complex fluidics and electronic interfaces required for remote dosage control.
Timeline
October 29-30, 2026: The PODD 2026 conference takes place in Boston.
October 30, 2026: Liz Proos presents at 2:30 p.m. ET.
The Tech Race
The DARE-IDDS platform joins a competitive landscape of implantable, remotely managed drug delivery systems designed to displace daily injection regimens. It follows the precedent of the 16th annual PODD conference, which focuses on the rapid integration of electronics into long-term therapeutic hardware.
As a device in preclinical testing, this technology is not yet available for patient use or clinical application. Users should monitor future announcements regarding regulatory filings to track when this contraceptive option might enter human trials.
The takeaway
The development of long-acting, wirelessly managed implants signals a shift in chronic disease management away from daily patient intervention. Investors and medical professionals should monitor the presentation at the PODD 2026 conference for specific progress metrics toward human feasibility trials.
Further reading
Explore the latest developments in Biotech to understand how implantable platforms are changing drug delivery.
Source note: This article includes information reported by The Manila times.
Live Poll
Would you trust an implantable device to manage your long-term medication doses instead of manual injections?
